| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110
CD47 has been implicated in both positive and negative regulation of T cells as well as in T cell death. To clarify the role of CD47 in T cell function, we have studied the mechanism of T cell death in response to CD47 ligands, including mAb 1F7, thrombospondin-1, and a CD47 agonist peptide derived from it. CD47-/- Jurkat T cells (JINB8) were resistant to killing by all three ligands, indicating the essential role of CD47. Primary human T cells were also killed by CD47 ligands, but only after activation with anti-CD3. CD47-mediated cell death occurred without active caspases, DNA fragmentation, or Bcl-2 degradation. Pretreatment of Jurkat and primary T cells with pertussis toxin (PTX) prevented CD47-mediated death, indicating the involvement of Gi
. Pretreatment of T cells with 8-bromo cAMP, forskolin, or 3-isobutyl-1-methylxanthine prevented the CD47-mediated apoptosis, and 1F7 dramatically reduced intracellular cAMP levels, an effect reversed with PTX. H89 and protein kinase A (PKA) inhibitor peptide, a specific PKA inhibitor, prevented rescue of T cells by PTX, 8-bromo cAMP, and forskolin, indicating a direct role for one or more PKA substrates. Thus, CD47-mediated killing of activated T cells occurs by a novel pathway involving regulation of cAMP levels by heterotrimeric Gi with subsequent effects mediated by PKA.
This article has been cited by other articles:
|
|
 |
|
  M. Bras, V. J. Yuste, G. Roue, S. Barbier, P. Sancho, C. Virely, M. Rubio, S. Baudet, J. E. Esquerda, H. Merle-Beral, et al. Drp1 Mediates Caspase-Independent Type III Cell Death in Normal and Leukemic Cells Mol. Cell. Biol., October 15, 2007; 27(20): 7073 - 7088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. I. Stenina, E. J. Topol, and E. F. Plow Thrombospondins, Their Polymorphisms, and Cardiovascular Disease Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 1886 - 1894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lamy, A. Foussat, E. J. Brown, P. Bornstein, M. Ticchioni, and A. Bernard Interactions between CD47 and Thrombospondin Reduce Inflammation J. Immunol., May 1, 2007; 178(9): 5930 - 5939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van Amerongen and A. Berns TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes & Dev., August 1, 2006; 20(15): 1975 - 1981. [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Manna, J. Dimitry, P.-A. Oldenborg, and W. A. Frazier CD47 Augments Fas/CD95-mediated Apoptosis J. Biol. Chem., August 19, 2005; 280(33): 29637 - 29644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Saumet, M. B. Slimane, M. Lanotte, J. Lawler, and V. Dubernard Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/{alpha}v{beta}3 in promyelocytic leukemia NB4 cells Blood, July 15, 2005; 106(2): 658 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Brooke, J. D. Holbrook, M. H. Brown, and A. N. Barclay Human Lymphocytes Interact Directly with CD47 through a Novel Member of the Signal Regulatory Protein (SIRP) Family J. Immunol., August 15, 2004; 173(4): 2562 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. McDonald, A. Zheleznyak, and W. A. Frazier Cholesterol-independent Interactions with CD47 Enhance {alpha}v{beta}3 Avidity J. Biol. Chem., April 23, 2004; 279(17): 17301 - 17311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Conant, C. St. Hillaire, H. Nagase, R. Visse, D. Gary, N. Haughey, C. Anderson, J. Turchan, and A. Nath Matrix Metalloproteinase 1 Interacts with Neuronal Integrins and Stimulates Dephosphorylation of Akt J. Biol. Chem., February 27, 2004; 279(9): 8056 - 8062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Manna and W. A. Frazier CD47 Mediates Killing of Breast Tumor Cells via Gi-Dependent Inhibition of Protein Kinase A Cancer Res., February 1, 2004; 64(3): 1026 - 1036. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
